NE-DESIGN-DATA
23.5.2017 14:02:47 CEST | Business Wire | Press release
Design Data, a leader in 3D steel detailing and Building Information Modeling (BIM) software, announced that the Steel Construction Institute (SCI) has recently assessed Design Data’s SDS/2 2016 software for connection design.
SDS/2 takes a uniquely intelligent approach in its connection design by considering framing conditions and erectability, automatically performing clash prevention as a part of its connection design. In addition, SDS/2 can value engineer the connections on a project, helping users to design the most economical connections to fabricate and erect.
SCI’s process involved reviewing connection design output in depth for each connection type: partial depth end plates, fin plates, column splices, beam splices, bracing connections, and bolted moment connections (end plates). Each connection was reviewed in detail for numerical correctness for the specific arrangement, but also to demonstrate that important principles common to all connections were correctly implemented.
SCI’s assessment was made in accordance with Eurocode 3: Design of steel structures, BS EN 1993, and the relevant UK National Annexes. Additionally, the “Green Books” were used as reference documents, being referenced in the U.K. National Annex and the de facto standard in the U.K.
“Achieving SCI Assessed status is a key advantage for us entering the U.K. and European markets,” said Damon Scaggs, president of Design Data. “With incorporating European design codes for the first time into SDS/2 — which already implements American, Canadian and Australian design codes — it was important to subject the software to the rigorous and extensive testing SCI conducted. This will help give our new European customers the confidence in our connections that our customers around the world have had for more than 30 years.”
According to the SCI Assessed website, “SCI Assessed” is an established quality mark that is awarded to testify that manufacturers' technical data has been independently verified by SCI. The scheme provides reliability for the range of performance data offered by suppliers particularly where, for example, the product is new or the values are based on calculation methods outside the scope of established standards.
About Design Data
Design Data, a Nemetschek company, is a leading software innovator for the steel industry's fabrication, detailing and engineering sectors. SDS/2 software products provide automatic connection optimization, detailing, engineering information, fabrication data and much more, reducing the time required to design, detail, fabricate and erect steel. Founded in 1981 and headquartered in Lincoln, Nebraska, USA, the company serves customers in 17 countries. Information on Design Data and SDS/2 can be found at: www.sds2.com .
About SCI
SCI has been a trusted, independent source of information and engineering expertise globally for over 30 years, and remains the leading, independent provider of technical expertise and disseminator of best practice to the steel construction sector. SCI offers comprehensive advice, technical information, consultancy services and membership for manufacturers, engineers and designers for every aspect of steel construction.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170523005367/en/
Contact:
Design Data
Damon Scaggs, 402-441-4000
President
Fax:
402-441-4045
damon@sds2.com
www.sds2.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom